WO2021145319A1 - 細胞培養用培地組成物 - Google Patents
細胞培養用培地組成物 Download PDFInfo
- Publication number
- WO2021145319A1 WO2021145319A1 PCT/JP2021/000744 JP2021000744W WO2021145319A1 WO 2021145319 A1 WO2021145319 A1 WO 2021145319A1 JP 2021000744 W JP2021000744 W JP 2021000744W WO 2021145319 A1 WO2021145319 A1 WO 2021145319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- day
- medium
- cells
- bfgf
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 239000006143 cell culture medium Substances 0.000 title claims abstract 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 106
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 106
- 210000004027 cell Anatomy 0.000 claims description 120
- 239000002609 medium Substances 0.000 claims description 95
- 239000013028 medium composition Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 31
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 31
- 238000004114 suspension culture Methods 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 12
- 210000004504 adult stem cell Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 description 26
- 238000003756 stirring Methods 0.000 description 14
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 13
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 10
- 210000003716 mesoderm Anatomy 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 238000012136 culture method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000009331 sowing Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- -1 etc.) Chemical compound 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004966 intestinal stem cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- NLOGSHMIAWCODV-UHFFFAOYSA-N 2-piperazin-4-ium-1-ylethanesulfonate Chemical compound OS(=O)(=O)CCN1CCNCC1 NLOGSHMIAWCODV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 101100350613 Arabidopsis thaliana PLL1 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102100036462 Delta-like protein 1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102220621903 N-acetylglucosamine-6-sulfatase_S94I_mutation Human genes 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- UNYNVICDCJHOPO-UHFFFAOYSA-N quabalactone III Natural products CC1OC(=O)C(O)=C1C UNYNVICDCJHOPO-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 102220004441 rs121918684 Human genes 0.000 description 1
- 102200031779 rs3204853 Human genes 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Definitions
- the present invention relates to a medium composition for cells, and more particularly to a medium composition for high-density suspension culture of cells.
- Patent Document 1 reports a method for culturing stem cells, which comprises treating the stem cells with a ROCK inhibitor in a medium.
- Patent Document 2 reports a high-density culture method of animal cells by adding glucose and / or a specific amino acid to a medium in 2018 (Patent Document 2).
- Patent Document 2 is one of the very excellent methods as a high-density culture method for animal cells including pluripotent stem cells, but this time, the present inventors have reexamined the method. An attempt was made to develop a more preferable high-density culture method for cells.
- the present inventors have determined the amount of basic fibroblast growth factor (bFGF) previously recommended in the art in high-density culture by suspension culture of cells.
- bFGF basic fibroblast growth factor
- the addition of a large amount of bFGF can maintain the undifferentiated state of the pluripotent stem cells cultured at high density very well, and the addition of a large amount of bFGF was added.
- pluripotent stem cells prepared by high-density culture in a medium have extremely good differentiation potential, and further research was carried out based on such findings to complete the present invention. That is, the present invention is as follows.
- a medium composition for cell culture which comprises 150 ng / mL or more of basic fibroblast growth factor (bFGF) or a stabilized bFGF having a concentration equivalent to that of bFGF.
- the medium composition according to [1] which is used for suspension culture.
- the cell density of cells suspension culture is 6.0 ⁇ 10 5 cells / mL or more, [3] the medium composition.
- [6] A method for culturing cells, which comprises suspending and culturing cells in the medium composition according to [1]. [7] The method according to [6], wherein a stabilized bFGF having a bFGF of 10 to 1000 ng / mL / day or a concentration equivalent to that of bFGF is added to the medium. [8] a cell density of pluripotent stem cells suspension culture is 6.0 ⁇ 10 5 cells / mL or more, [6] or [7] The method according. [9] The method according to any one of [6] to [8], wherein the cell is a pluripotent stem cell, an adult stem cell, or a progenitor cell.
- cells can be prepared extremely efficiently. Further, according to the present invention, high-quality pluripotent stem cells having a good undifferentiated state and good differentiation ability can be prepared very efficiently.
- FIG. 3 is a diagram showing that the desired effect of the present invention can be obtained even by using stabilized bFGF.
- FIG. 4 is a diagram showing changes over time in the number of cells (VCD: Viable Cell Density) when iPS cells are cultured in a medium containing a high concentration of bFGF.
- FIG. 5 is a diagram showing the expression level of CD30 in iPS cells cultured in a medium containing a high concentration of bFGF.
- iPS cells cultured in a medium containing a high concentration of bFGF is a high density state of more than 1.0 ⁇ 10 7 cells / mL, high efficiency paraxial mesoderm (PM: Paraxial Mesoderm) It is a figure which shows that it was able to differentiate into.
- FIG. 7 is a diagram showing that cells induced to differentiate from iPS cells cultured in a medium containing a high concentration of bFGF highly express PLL1 (PM marker).
- suspension culture refers to a cell culture method performed in a state where cells do not adhere to a culture vessel.
- the suspension culture may or may not be accompanied by external pressure or vibration on the liquid medium, or shaking or rotation operation in the liquid medium.
- high density culture refers to culture at a cell density higher than that assumed in general cell culture. Dense criteria may differ depending on the kind or the like of the culture method (contact culture / suspension culture, etc.) or cells, for example, the case of suspension culture iPS cells, 6 ⁇ 10 5 cells / mL or more in the specification Culturing at a density of (preferably 2 ⁇ 10 6 cells / mL or higher) is defined as high density culture.
- pluripotent stem cell means a cell having the ability to differentiate into all the tissues and cells constituting the living body.
- pluripotent stem cells include, but are not limited to, embryonic stem cells (ES cells), embryonic germ cells (EG cells), and induced pluripotent stem cells (iPS cells).
- adult stem cell also referred to as somatic stem cell
- somatic stem cell means a cell having an ability to differentiate into a cell constituting a specific tissue (organ).
- adult stem cells include, but are not limited to, hematopoietic stem cells, nerve stem cells, reproductive stem cells, intestinal stem cells, epidermal stem cells, and mesenchymal stem cells.
- the "progenitor cell” means a cell in the process of differentiating from the pluripotent stem cell or adult stem cell described above into a specific somatic cell or germ cell.
- the present invention is a medium composition for cell culture containing a basic fibroblast growth factor (bFGF) of 150 ng / mL or more, or a stabilized bFGF having a concentration equivalent to that of bFGF. (Hereinafter, it may be referred to as "medium composition of the present invention").
- bFGF basic fibroblast growth factor
- the medium composition of the present invention can be prepared by adding a very high concentration of bFGF to a general basal medium for cells.
- the medium for cells used in preparing the medium composition of the present invention may be prepared by a method known per se according to the cells to be cultured, or may be a commercially available product. ..
- DMEM Dulbecco's Modified Eagle's Medium
- F12 Ham's Nutrition Mixture F12
- DMEM / F12 medium McCoy's medium
- McCoy's McCoy's medium
- 5A Medium Minim's Essential Medium (MEM), Eagle's Minim's Essential Medium (EMEM), ⁇ 's Modified Eagle's Minim's Medium Essential Medium' ⁇ MEM), Roswell Park Memorial Institute (RPMI) 1640 medium, Iskov's Modified Dulbecco's Medium (IMDM), MCDB131 medium, William's Medium E (Willi's Medium) ), Fisher's Medium, and the like.
- the medium for culturing stem cells for example, STEMPRO (registered trademark) hESC SFM medium (Life Technologies), mTeSR1 medium (STEMCELL Technologies), TeSR2 medium (STEMCELL Technologies-TechLegies), TeSR2 Medium (STEMCELL Technologies) , Essential 8 medium (Life Technologies), HESCGRO (trademark) Serum-Free Medium for hES cells (Millipore), Pluristem (trademark) Human ES / iPS Medium (EMD) Medium (Biological Industries Islael Beat-Haemek), NutriStem (trademark) XF / FF Culture Medium (Stemment), AF NutriStem (registered trademark) hESC XF Medium Medium (Biological) Medium Biomedical Co., Ltd.), StemFit (registered trademark) AK03N medium (Ajinomoto Co., Ltd.), hESF9 medium, hESF-FX medium, CDM medium, DEF-CS 500 Xeno-
- the amount of bFGF contained in the medium for culturing cells is at most about 100 ng / mL. This is because it is believed that the addition of bFGF at higher concentrations has a constant effect on cell proliferation and / or undifferentiation.
- the lower limit of the concentration of bFGF contained in the medium composition of the present invention is usually 150 ng / mL, preferably 200 ng / mL, more preferably 250 ng / mL, still more preferably 275 ng / mL, and particularly preferably 300 ng / mL. It is possible, and it may be more than this.
- the upper limit is not particularly limited, but from the viewpoint of cost and the like, it may be usually 1500 ng / mL, preferably 1000 ng / mL, more preferably 800 ng / mL, still more preferably 600 ng / mL, and particularly preferably 500 ng / mL.
- the concentration of bFGF in the medium composition of the present invention is usually 150-1500 ng / mL, preferably 200-1000 ng / mL, more preferably 250-800 ng / mL, even more preferably 275-600 ng / mL, in particular. It can preferably be 300-500 ng / mL.
- the bFGF added to the medium composition of the present invention may be stabilized.
- the stabilized bFGF that can be added to the medium composition of the present invention may be produced by a method known per se, or may be a commercially available product. Suitable commercially available products include, but are not limited to, Heat Stable Recombinant Human bFGF (manufactured by Thermo Fisher Scientific). Moreover, as another example of stabilized bFGF, "FGF2-G3" can be mentioned.
- FGF2-G3 is a mutant bFGF protein having nine amino acid mutations (R31L, V52T, E54D, H59F, S94I, L92Y, C96N, S109E, T121P) as compared to wild-type bFGF. Although not bound by theory, FGF2-G3 has been reported to exhibit comparable activity at about 40% usage compared to unstabilized wild-type bFGF (Hui). -Hsuan Kuo et al., Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture).
- a suitable concentration range of stabilized bFGF may be a concentration that exhibits a cell proliferation promoting effect and / or an undifferentiated maintaining effect equivalent to that of unstabilized bFGF.
- a suitable concentration range when using stabilized bFGF refer to the above concentration range and confirm the difference in effect between unstabilized bFGF and stabilized bFGF by a method known per se, etc. Therefore, those skilled in the art can set it as appropriate.
- the concentration of stabilized bFGF in the medium composition can vary depending on the means and degree of stabilization of bFGF, but is usually achieved when the above-mentioned unstabilized bFGF concentration range is adopted.
- the concentration range in which the desired effect of the present invention (cell proliferation promoting effect and / or undifferentiated maintenance effect) can be obtained may be appropriately set.
- the determination of the stabilized bFGF concentration range may be determined as follows: (1) Quantify the effect (that is, cell proliferation promoting effect and / or undifferentiated maintaining effect) when a medium composition containing unstabilized bFGF is used (the effect is quantified in Examples of the present application described later. The method used in (can be adopted), (2) Using stabilized bFGF instead of unstabilized bFGF, the same test as in (1) is performed, and stabilized to achieve the same level of effect as the effect quantified in (1). The concentration of bFGF is determined.
- the lower limit of the concentration of stabilized bFGF contained in the medium composition of the present invention is usually 75 ng / mL, preferably 100 ng / mL, more preferably 125 ng / mL, still more preferably 138 ng / mL, in particular. It can preferably be 150 ng / mL and may be higher.
- the upper limit is not particularly limited, but from the viewpoint of cost and the like, it may be usually 750 ng / mL, preferably 500 ng / mL, more preferably 400 ng / mL, still more preferably 300 ng / mL, and particularly preferably 250 ng / mL.
- the concentration of bFGF in the medium composition of the present invention is usually 75-750 ng / mL, preferably 100-500 ng / mL, more preferably 125-400 ng / mL, still more preferably 138-300 ng / mL, in particular. It can preferably be 150-250 ng / mL.
- the lower limit of the concentration of stabilized bFGF contained in the medium composition of the present invention is usually 50 ng / mL, preferably 67 ng / mL, more preferably 84 ng / mL, even more preferably 92 ng / mL, in particular. It can preferably be 100 ng / mL and may be higher.
- the upper limit is not particularly limited, but from the viewpoint of cost and the like, it may be usually 500 ng / mL, preferably 334 ng / mL, more preferably 267 ng / mL, still more preferably 200 ng / mL, and particularly preferably 167 ng / mL.
- the concentration of bFGF in the medium composition of the present invention is usually 50-500 ng / mL, preferably 67-334 ng / mL, more preferably 84-267 ng / mL, still more preferably 92-200 ng / mL, in particular. It can be preferably 100 to 167 ng / mL.
- the lower limit of the concentration of stabilized bFGF contained in the medium composition of the present invention is usually 38 ng / mL, preferably 50 ng / mL, more preferably 63 ng / mL, even more preferably 69 ng / mL, in particular. It can preferably be 75 ng / mL and may be higher.
- the upper limit is not particularly limited, but from the viewpoint of cost and the like, it may be usually 375 ng / mL, preferably 250 ng / mL, more preferably 200 ng / mL, still more preferably 150 ng / mL, and particularly preferably 125 ng / mL.
- the concentration of bFGF in the medium composition of the present invention is usually 38-375 ng / mL, preferably 50-250 ng / mL, more preferably 63-200 ng / mL, still more preferably 69-150 ng / mL, in particular. It can preferably be 75-125 ng / mL.
- bFGF can be stabilized by separately adding a compound that contributes to the stabilization of bFGF to the medium.
- a sulfated compound eg, a sulfated polysaccharide such as sodium dextran sulfate, a sulfated polymer such as a sulfo group-containing polyvinyl alcohol, a sulfated product of a sugar lactone such as gluconolactone-SO 3 NA, etc.
- a sulfated compound eg, a sulfated polysaccharide such as sodium dextran sulfate, a sulfated polymer such as a sulfo group-containing polyvinyl alcohol, a sulfated product of a sugar lactone such as gluconolactone-SO 3 NA, etc.
- components preferable for cell proliferation can be further added.
- Such components include, for example, sugars such as glucose, fructose, sucrose, maltose; amino acids such as asparagine, aspartic acid, glutamine, glutamic acid; proteins such as albumin and transformin; peptides such as glycylglycylglycine and soybean peptide; serum; Vitamin such as choline, vitamin A, vitamin B group (thiamine, riboflavin, pyridoxin, cyanocobalamine, biotin, folic acid, pantothenic acid, nicotine amide, etc.), vitamin C, vitamin E; Lipids such as cholesterol; Inorganic salts such as sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium dihydrogen phosphate; trace elements such as zinc, copper, selenium; N, N-bis (2-hydroxyethyl) -2 -Aminoethanesul
- Antibiotics such as; Type I collagen, Type II collagen, fibronectin, laminin, poly-L-lysine, poly-D-lysine and other cell adhesion factors and extracellular matrix components; interleukin, fibroblast growth factor (FGF) , Transforming Growth Factor (HGF), Transforming Growth Factor (TGF) - ⁇ , Transforming Growth Factor (TGF) - ⁇ , Vascular Endothelial Growth Factor (VEGF), Actibin A and other cytokines and growth factors; Examples thereof include hormones such as estradiol, progesterone, glucagon, and insulin, and an appropriate component can be selected and used according to the type of cells to be cultured.
- FGF fibroblast growth factor
- HGF Transforming Growth Factor
- TGF Transforming Growth Factor
- TGF Transforming Growth Factor
- TGF Transforming Growth Factor
- VEGF Vascular Endothelial Growth Factor
- Actibin A and other cytokines and growth factors
- examples thereof
- the medium composition of the present invention may contain choline (or a salt thereof) at the following concentration (in the case of a choline salt, an amount converted to a free form): [1] 1 to 100 mg / L, 10 to 100 mg / L, 20 to 100 mg / L, 30 to 100 mg / L, 40 to 100 mg / L, 50 to 100 mg / L, 60 to 100 mg / L, 70 to 100 mg / L , 80-100 mg / L, 90-100 mg / L; [2] 1 to 90 mg / L, 10 to 90 mg / L, 20 to 90 mg / L, 30 to 90 mg / L, 40 to 90 mg / L, 50 to 90 mg / L, 60 to 90 mg / L, 70 to 90 mg / L , 80-90 mg / L; [3] 1 to 80 mg / L, 10 to 80 mg / L, 20 to 80 mg / L, 30 to 80 mg / L, 40 to 80 mg / L, 50 to 80
- D-glucose and five amino acids may be additionally added to the medium composition of the present invention.
- the amount of these components added is appropriately set according to the purpose of culture and various culture conditions (eg, cell density, frequency of medium exchange), etc., with reference to the corresponding description in "2. Cell culture method” below. do it.
- the cells can be, but are not limited to, pluripotent stem cells, adult stem cells, or progenitor cells.
- the pluripotent stem cell can be an embryonic stem cell (ES cell) or an iPS cell, preferably an iPS cell.
- ES cell embryonic stem cell
- iPS cell preferably an iPS cell.
- Adult stem cells can be, but are not limited to, hematopoietic stem cells, neural stem cells, reproductive stem cells, intestinal stem cells, epidermal stem cells, or mesenchymal stem cells.
- the origin of pluripotent stem cells, adult stem cells, and progenitor cells is also not particularly limited, but those derived from mammals are preferable, and those derived from humans are more preferable.
- the medium composition of the present invention can be provided as a medium for suspension culture of pluripotent stem cells.
- the medium composition of the present invention can be provided as a medium for suspension culture of pluripotent stem cells and for high-density culture.
- the medium composition of the present invention has a function of maintaining a high-density suspension culture of pluripotent stem cells in a preferable state, and can realize very good cell proliferation of pluripotent stem cells.
- the pluripotent stem cells proliferated using the medium composition of the present invention maintain a good undifferentiated state. That is, the pluripotent stem cells proliferated using the medium composition of the present invention are of high quality and therefore can be suitably used for, for example, regenerative medicine.
- the medium composition of the present invention is a medium composition for maintaining undifferentiated maintenance of pluripotent stem cells, or a medium for maintaining undifferentiated maintenance of pluripotent stem cells and promoting proliferation. It can be said to be a composition.
- the undifferentiated state of pluripotent stem cells may be confirmed by a method known per se. For example, those skilled in the art can easily confirm by confirming the expression of known markers (eg, CD30, Oct3/4, Nanog, etc.) indicating an undifferentiated state.
- the medium of the present invention may be provided in a liquid state, or may be prepared in a state of being more concentrated than the concentration at the time of use or in a solid state such as lyophilized powder, and a solvent such as water may be used at the time of use. It can also be diluted with water, or dissolved or dispersed in a solvent such as water. Moreover, since bFGF is easily thermally decomposed, it can be added immediately before the use of the medium.
- the present invention also provides a cell culture method (hereinafter, may be referred to as “the method of the present invention”), which comprises suspending and culturing cells using the medium composition of the present invention. ..
- bFGF is additionally added to the medium being cultured.
- the amount of bFGF additionally added is not particularly limited as long as the desired effect of the present invention can be obtained, but is usually 10 to 1000 ng / mL / day, preferably 30 to 800 ng / mL / day, more preferably 50 to 600 ng. It can be / mL / day, more preferably 70-500 ng / mL / day, particularly preferably 105-420 ng / mL / day.
- stabilized FGF can be additionally added.
- the amount of additional stabilized bFGF added may vary depending on the means and degree of stabilization of bFGF, but is usually achieved when the above-mentioned amount of unstabilized bFGF added is adopted.
- the amount of addition that can obtain the same effect as the desired effect of the present invention may be appropriately set.
- stabilized bFGF is additionally added to the medium being cultured.
- the amount of stabilized bFGF additionally added is not particularly limited as long as the desired effect of the present invention can be obtained, but is usually 5 to 500 ng / mL / day, preferably 15 to 400 ng / mL / day, more preferably.
- the amount of stabilized bFGF additionally added is not particularly limited as long as the desired effect of the present invention is obtained, but is usually 4 to 334 ng / mL / day, preferably 4 to 334 ng / mL / day.
- the amount of stabilized bFGF additionally added is not particularly limited as long as the desired effect of the present invention is obtained, but is usually 3 to 250 ng / mL / day, preferably 3 to 250 ng / mL / day.
- the above-mentioned additional addition of bFGF or stabilized bFGF can be performed using the medium of the present invention at the timing of medium replacement.
- the frequency of medium exchange may be appropriately determined according to the cell density, cell type, etc., and is not particularly limited, but the concentration of active bFGF in the medium is the maintenance of proliferation and / or undifferentiated state of pluripotent stem cells. It is performed at least once a day (preferably at least twice or more) and 50 to 100% (preferably) of the medium in use at the time of the medium exchange, in order to avoid a decrease to the extent that the medium is adversely affected.
- the frequency of medium exchange is at least once a day (eg, once, twice, or three times), and at the time of the medium exchange, 70 to 100% of the medium in use is the medium of the present invention.
- D-glucose and five amino acids may be additionally added to the medium of the present invention.
- Glucose (or a salt thereof) is usually 0.1 g / L / day to 900 g / L / day, preferably 1 g / L / day to 200 g / L / day, more preferably 1 g / L in terms of glucose concentration. It can be added to the medium of the present invention so as to have a concentration of / day to 20 g / L / day.
- 5 kinds of amino acids are usually 0.1 mg / L / day to the concentration of tryptophan (concentration converted to free tryptophan) with respect to the medium.
- 11000 mg / L / day preferably 1 mg / L / day to 1000 mg / L / day, more preferably 1 mg / L / day to 100 mg / L / day, with a concentration of cysteine (concentration converted to free cysteine).
- 0.1 mg / L / day to 425,000 mg / L / day preferably 1 mg / L / day to 1000 mg / L / day, more preferably 1 mg / L / day to 100 mg / L / day, cysteine or cystine concentration ( The concentration converted to cysteine in the free form) is usually 0.1 mg / L / day to 280000 mg / L / day, preferably 1 mg / L / day to 1000 mg / L / day, and more preferably 1 mg / L / day to 100 mg.
- the concentration of methionine is usually 0.1 mg / L / day to 55000 mg / L / day, preferably 1 mg / L / day to 1000 mg / L / day, and more. It is preferably 1 mg / L / day to 100 mg / L / day, and the concentration of arginine (concentration converted to free arginine) is usually 0.1 mg / L / day to 150,000 mg / L / day, preferably 1 mg / L /. It can be added to the medium of the present invention so as to have a day to 2000 mg / L / day, more preferably 1 mg / L / day to 200 mg / L / day.
- choline eg, choline chloride, etc.
- the amount of choline added to the medium is usually 0.01 to 1000000 mg / L / day, preferably 0.1 to 1000 mg / L / day, more preferably.
- Is 1 to 100 mg / L / day (for example, [1] 1 to 100 mg / L / day, 10 to 100 mg / L / day, 20 to 100 mg / L / day, 30 to 100 mg / L / day, 40 to 100 mg / L / day, 50 to 100 mg / L / day , 60-100 mg / L / day, 70-100 mg / L / day, 80-100 mg / L / day, 90-100 mg / L / day; [2] 1 to 90 mg / L / day, 10 to 90 mg / L / day, 20 to 90 mg / L / day, 30 to 90 mg / L / day, 40 to 90 mg / L / day, 50 to 90 mg / L / day , 60-90 mg / L / day, 70-90 mg / L / day, 80-90 mg / L / day; [3] 1 to 80 mg / L / day, 10 to 80 mg / L
- the pluripotent stem cell can be an embryonic stem cell (ES cell) or an iPS cell, preferably an iPS cell.
- ES cell embryonic stem cell
- iPS cell preferably an iPS cell.
- pluripotent stem cells suspension-cultured using the medium composition of the present invention not only proliferate efficiently, but also have a good state even in a state of maintaining undifferentiation. Therefore, the method of the present invention can be rephrased as a method for promoting proliferation of pluripotent stem cells and / or maintaining undifferentiated cells.
- the culture conditions are not particularly limited, and a method known per se may be selected according to the cell type, cell density, culture method (adhesive culture / suspension culture, etc.) and the like.
- the culture temperature can be usually 25 ° C. to 39 ° C., preferably 33 ° C. to 39 ° C.
- the carbon dioxide concentration can be usually 4% by volume to 10% by volume, preferably 4% by volume to 6% by volume.
- the oxygen concentration may be usually 1% by volume to 25% by volume, preferably 4% by volume to 20% by volume.
- iPS cells induced pluripotent stem cells
- bFGF induced pluripotent stem cells
- the number of viable cells was measured using a vi-CELL TM XR (Beckman Coulter), a vi-dead cell autoanalyzer.
- a vi-CELL TM XR Beckman Coulter
- StemFit Basic03 does not contain bFGF.
- FIG. 1 shows the results of verifying the effect of bFGF concentration on the proliferation of iPS cells in a single series. Increasing the bFGF concentration in the medium from 100 ng / mL to 300 ng / mL promoted the proliferation of iPS cells.
- the expression rate of CD30 stained as described above was measured using Attune NxT Flow Cytometer (Thermo Fisher Scientific). The result of verifying the influence of the addition amount of bFGF on the expression of CD30 in a series is shown in FIG.
- the expression of CD30 in iPS cells was maintained as high as about 80% at the 10th day of culture.
- StemFit Basic03 + 100 ng / mL bFGF medium replace once or twice daily
- StemFit Basic03 + 100 ng / mL stabilized bFGF medium replace 70% of the medium once daily
- 40 mg / L / day Trp for both groups. 40 mg / L / day Ser, 40 mg / L / day Cys, 40 mg / L / day Met, 160 mg / L / day Arg, 4 g / L / day D-glucose were added.
- Cells were collected on the 10th day of culture, and CD30, which is an iPS cell marker, was stained as follows.
- FIG. 3 shows the results of verifying the effect of stabilized bFGF on the expression of CD30 in duplicate. It was shown that the expression of CD30 was maintained even by changing the medium once a day by using stabilized bFGF. In other words, it has been shown that it is also effective to use stabilized bFGF instead of adding a large amount of bFGF.
- Example 4 Evaluation of differentiation potential of iPS cells cultured using a medium enriched with bFGF.
- the number of living cells was quantified using Vi-CELL TM XR (Beckman Coulter), a living and dead cell autoanalyzer, and the expression ratio of CD30, which is an iPS cell marker, was measured.
- FIGS. 4 and 5 Results on iPS cell proliferation and undifferentiated markers are shown in FIGS. 4 and 5. As shown in FIGS. 1 and 2, by culturing iPS cells in a medium containing a high concentration of bFGF, 8.8 to 9.7 ⁇ 10 ⁇ 6 cells / mL while maintaining the undifferentiated state of iPS cells. High-density culture was realized.
- FIGS. 6 and 7 The results regarding cell proliferation and differentiation markers associated with differentiation into PM are shown in FIGS. 6 and 7.
- the iPS cells cultured in a medium containing a high concentration of bFGF were able to differentiate from iPS cells to PM with high efficiency at a high density of more than 1.0 ⁇ 10 ⁇ 7 cells / mL.
- cells can be prepared extremely efficiently. Further, according to the present invention, high-quality pluripotent stem cells in which the undifferentiated state is well maintained can be prepared very efficiently.
Abstract
Description
すなわち、本発明は以下の通りである。
[2]浮遊培養用である、[1]記載の培地組成物。
[3]高密度培養用である、[1]または[2]記載の培地組成物。
[4]浮遊培養される細胞の細胞密度が6.0×105cells/mL以上である、[3]記載の培地組成物。
[5]細胞が、多能性幹細胞、成体幹細胞、または前駆細胞である、[1]~[4]のいずれか記載の培地組成物。
[6][1]記載の培地組成物において、細胞を浮遊培養することを含む、細胞の培養方法。
[7]bFGFが10~1000ng/mL/dayで、または、該濃度のbFGFと同等の効果を奏する濃度の安定化されたbFGFが培地に添加される、[6]記載の方法。
[8]浮遊培養される多能性幹細胞の細胞密度が6.0×105cells/mL以上である、[6]または[7]記載の方法。
[9]細胞が多能性幹細胞、成体幹細胞、または前駆細胞である、[6]~[8]のいずれか記載の方法。
本明細書において、「浮遊培養」とは、培養容器に対して細胞が接着しない状態で行われる細胞培養方法をいう。本発明において、浮遊培養は、液体培地に対する外部からの圧力や振動、または、当該液体培地中での振とうや回転操作を伴ってもよいし、伴わなくてもよい。
本発明は、塩基性線維芽細胞増殖因子(bFGF)を150ng/mL以上、または該濃度のbFGFと同等の効果を奏する濃度の安定化されたbFGFを含む、細胞培養用培地組成物(以下、「本発明の培地組成物」と称することがある)を提供する。
(1)安定化されていないbFGFを含有する培地組成物を用いた場合の効果(即ち、細胞増殖促進効果および/または未分化維持効果)を定量する(効果の定量は、後述する本願実施例で用いられた方法を採用することができる)、
(2)安定化されていないbFGFの代わりに、安定化されたbFGFを用いて(1)と同様の試験を行い、(1)で定量された効果と同等程度の効果を達成する安定化されたbFGFの濃度を決定する。
[1]1~100mg/L、10~100mg/L、20~100mg/L、30~100mg/L、40~100mg/L、50~100mg/L、60~100mg/L、70~100mg/L、80~100mg/L、90~100mg/L;
[2]1~90mg/L、10~90mg/L、20~90mg/L、30~90mg/L、40~90mg/L、50~90mg/L、60~90mg/L、70~90mg/L、80~90mg/L;
[3]1~80mg/L、10~80mg/L、20~80mg/L、30~80mg/L、40~80mg/L、50~80mg/L、60~80mg/L、70~80mg/L;
[4]1~70mg/L、10~70mg/L、20~70mg/L、30~70mg/L、40~70mg/L、50~70mg/L、60~70mg/L;
[5]1~60mg/L、10~60mg/L、20~60mg/L、30~60mg/L、40~60mg/L、50~60mg/L;
[6]1~50mg/L、10~50mg/L、20~50mg/L、30~50mg/L、40~50mg/L;
[7]1~40mg/L/、10~40mg/L、20~40mg/L、30~40mg/L;
[8]1~30mg/L/、10~30mg/L/、20~30mg/L;
[9]1~20mg/L、10~20mg/L)。
本発明はまた、本発明の培地組成物を用いて、細胞を浮遊培養することを含む、細胞の培養方法(以下、「本発明の方法」と称することがある)を提供する。
[1]1~100mg/L/day、10~100mg/L/day、20~100mg/L/day、30~100mg/L/day、40~100mg/L/day、50~100mg/L/day、60~100mg/L/day、70~100mg/L/day、80~100mg/L/day、90~100mg/L/day;
[2]1~90mg/L/day、10~90mg/L/day、20~90mg/L/day、30~90mg/L/day、40~90mg/L/day、50~90mg/L/day、60~90mg/L/day、70~90mg/L/day、80~90mg/L/day;
[3]1~80mg/L/day、10~80mg/L/day、20~80mg/L/day、30~80mg/L/day、40~80mg/L/day、50~80mg/L/day、60~80mg/L/day、70~80mg/L/day;
[4]1~70mg/L/day、10~70mg/L/day、20~70mg/L/day、30~70mg/L/day、40~70mg/L/day、50~70mg/L/day、60~70mg/L/day;
[5]1~60mg/L/day、10~60mg/L/day、20~60mg/L/day、30~60mg/L/day、40~60mg/L/day、50~60mg/L/day;
[6]1~50mg/L/day、10~50mg/L/day、20~50mg/L/day、30~50mg/L/day、40~50mg/L/day;
[7]1~40mg/L/day、10~40mg/L/day、20~40mg/L/day、30~40mg/L/day;
[8]1~30mg/L/day、10~30mg/L/day、20~30mg/L/day;
[9]1~20mg/L/day、10~20mg/L/day)
とすることができる。
以下の実施例では、bFGFによる人工多能性幹細胞(iPS細胞)の増殖効果および未分化維持能を評価した。iPS細胞として、iPSアカデミアジャパン社より購入した1210B2株を用いた。また、iPS細胞用培地として、市販のStemFit AK03N(味の素社)またはStemFit Basic03(味の素社)を用いた。
iPS細胞用30mLシングルユースバイオリアクター(ABLE:BWV-S03A)を用いて、StemFit AK03N+10μM Y-27632(Wako:034-24024)にiPS細胞1210B2株を6×105cells/mLの細胞密度で播種し、CO2インキュベーター内で37℃、CO2濃度=5%、攪拌速度=120rpmの条件下で攪拌培養した。播種2日目に7割の培地をStemFit AK03Nで交換した。播種3日目に細胞懸濁液10mLを新鮮なStemFit Basic03+100ng/mL bFGF(Peprotech)またはStemFit Basic03+300ng/mL bFGFに再懸濁し、バイオリアクターのambr15(sartorius:001-0881)に移し、37℃、pH=7.2、溶存酸素濃度=20%、攪拌速度=300rpmの条件下で攪拌培養を続けた。7割の各培地を1日2回交換し、さらに両群に40mg/L/day Trp(味の素社)、40mg/L/day Ser(味の素社)、40mg/L/day Cys(日本プロテイン社)、40mg/L/day Met(味の素社)、160mg/L/day Arg(味の素社)、4g/L/day D-グルコース(ナカライテスク社:16806-25)を添加した。培養5日目以降に生細胞数を生死細胞オートアナライザーのVi-CELLTM XR(ベックマン・コールター社)を用いて測定した。尚、StemFit Basic03はbFGFを含有しない。
iPS細胞用30mLシングルユースバイオリアクターを用いて、StemFit AK03N+10μM Y-27632にiPS細胞1210B2株を6×105cells/mLの細胞密度で播種し、CO2インキュベーター内で37℃、CO2濃度=5%、攪拌速度=120rpmの条件下で攪拌培養した。播種2日目に7割の培地をStemFit AK03Nで交換した。播種3日目に細胞懸濁液10mLを新鮮なStemFit Basic03+100ng/mL bFGF(Peprotech)またはStemFit Basic03+150ng/mL bFGFに再懸濁し、バイオリアクターのambr15に移し、37℃、pH=7.2、溶存酸素濃度=20%、攪拌速度=300rpmの条件下で攪拌培養を続けた。1日1回、各培地で7割の培地を交換し、さらに両群に40mg/L/day Trp、40mg/L/day Ser、40mg/L/day Cys、40mg/L/day Met、160mg/L/day Arg、4g/L/day D-グルコースを添加した。培養10日目に細胞を回収し、iPS細胞マーカーであるCD30を以下のように染色した。
iPS細胞用30mLシングルユースバイオリアクターを用いて、StemFit AK03N+10uM Y-27632にiPS細胞1210B2株を6×105cells/mLの細胞密度で播種し、CO2インキュベーター内で37℃、CO2濃度=5%、攪拌速度=120rpmの条件下で攪拌培養した。播種2日目に7割の培地をStemFit AK03Nで交換した。播種3日目に細胞懸濁液10mLを新鮮なStemFit Basic03+100ng/mL bFGF(Peprotech)またはStemFit Basic03+100ng/mL Heat Stable Recombinant Human bFGF(Thermo Fisher Scientific)(以下、安定化bFGF)に再懸濁し、マイクロバイオリアクターのambr15に移し、37℃、pH=7.2、溶存酸素濃度=20%、攪拌速度=300rpmの条件下で攪拌培養を続けた。StemFit Basic03+100ng/mL bFGFの培地については1日1または2回、StemFit Basic03+100ng/mL安定化bFGFの培地については1日1回7割の培地を交換し、さらに両群に40mg/L/day Trp、40mg/L/day Ser、40mg/L/day Cys、40mg/L/day Met、160mg/L/day Arg、4g/L/day D-グルコースを添加した。培養10日目に細胞を回収し、iPS細胞マーカーであるCD30を以下のように染色した。すなわち、2×105cellsを1.5mLエッペンチューブに分取して遠心後(400×g、4℃、5分間)、上清を除去して0.2%BSA(ナカライテスク:01281-84)を含むPBS(-)(ナカライテスク:14249-24)(以下、0.2%BSA-PBS)にPE Mouse anti-CD30(BD Biosciences:550041)を20%添加したものを20uL添加し、5~10回のピペッティングにより均一にして4℃遮光下で20分間静置した。0.5mL 0.2%BSA-PBSを添加して遠心後(400×g、4℃、5分間)、上清を除去し、0.2%BSA-PBSを300ul添加して5~10回のピペッティングにより均一にし、35umセルストレーナー付き5mLラウンドチューブに移した。上記のように染色したCD30の発現割合を、Attune NxT Flow Cytometer(Thermo Fisher Scientific)を用いて測定した。安定化bFGFがCD30の発現に与える影響を2連にて検証した結果を図3に示す。安定化bFGFを用いることで1日1回の培地交換でもCD30の発現が維持されていることが示された。換言すれば、多量のbFGFを添加する代わりに、安定化されたbFGFを使用することも有効であることが示された。
1.iPS細胞の高密度および未分化維持培養
iPS細胞用30mLシングルユースバイオリアクター(ABLE:BWV-S03A)を用いて、StemFit(登録商標)AK03N+10uM Y-27632(Wako:034-24024)にiPS細胞1210B2株を6×105cells/mLの細胞密度で播種し、CO2インキュベーター内で37℃、CO2濃度=5%、攪拌速度=120rpmの条件下で攪拌培養した。播種2日目に7割の培地をStemFit(登録商標)AK03Nで交換した。播種3日目に細胞懸濁液10mLを新鮮なStemFit(登録商標)AK03N+10mg/L Choline Chloride(富士フイルム和光純薬)+200ng/mL bFGF(Peprotech)に再懸濁し、マイクロバイオリアクターのambr15(sartorius:001-0881)に2連で移し、37℃、pH=7.2、溶存酸素濃度=4%、攪拌速度=300rpmの条件下で攪拌培養を続けた。7割の培地をStemFit(登録商標)AK03N+10mg/L Choline Chloride+200ng/mL bFGFで1日2回交換し、さらに両群に40mg/L/day Trp(味の素社)、40mg/L/day Ser(味の素社)、40mg/L/day Cys(日本プロテイン)、40mg/L/day Met(味の素社)、160mg/L/day Arg(味の素社)、18.6mg/L/day His(味の素社)、43.7mg/L/day Ile(味の素社)、47.3mg/L/day Leu(味の素社)、73.1mg/L/day Lys HCl(味の素社)、28.4mg/L/day Phe(味の素社)、42.3mg/L/day Val(味の素社)、4g/L/day D-グルコース(ナカライテスク)を添加した。培養7日目に生死細胞オートアナライザーのVi-CELLTM XR(ベックマン・コールター)を用いて生細胞数を定量し、またiPS細胞マーカーであるCD30の発現割合を測定した。
上記1.において培養した2連の細胞懸濁液を1連にまとめ、PMへ分化誘導した。具体的には、新鮮な分化1培地(AK02N・A液(味の素社)+20% StemFit For Differentiation(味の素社)+10uM CHIR99021(富士フイルム和光純薬)+30ng/mL アクチビンA(味の素社)+100ng/mL bFGF+300nM LDN-193189(富士フイルム和光純薬))に再懸濁し、37℃、pH=7.2、溶存酸素濃度=20%、攪拌速度=300rpmの条件下で攪拌培養を続けた。12時間後に7割の培地を分化1培地で交換し、さらにその6時間後に40mg/L/day Trp、40mg/L/day Ser、40mg/L/day Cys、40mg/L/day Met、160mg/L/day Arg、18.6mg/L/day His、43.7mg/L/day Ile、47.3 mg/L/day Leu、73.1mg/L/day Lys HCl、28.4mg/L/day Phe、42.3mg/L/day Val、4g/L/day D-グルコースを添加した。6時間後に、細胞懸濁液10mLを新鮮な分化2培地(AK02N・A液+20% StemFit For Differentiation+5uM CHIR99021+10uM SB431542(Stemgent)+100ng/mL bFGF+300nM LDN-193189)に再懸濁し、培養を続けた。12時間後に7割の培地を分化2培地で交換し、さらにその6時間後に40mg/L/day Trp、40mg/L/day Ser、40mg/L/day Cys、40mg/L/day Met、160mg/L/day Arg、18.6mg/L/day His、43.7mg/L/day Ile、47.3mg/L/day Leu、73.1mg/L/day Lys HCl、28.4mg/L/day Phe、42.3mg/L/day Val、4g/L/day D-グルコースを添加した。6時間後に生細胞数とPMマーカーであるDLL1の発現割合を測定した。
Claims (9)
- 塩基性線維芽細胞増殖因子(bFGF)を150ng/mL以上、または該濃度のbFGFと同等の効果を奏する濃度の安定化されたbFGFを含む、細胞培養用培地組成物。
- 浮遊培養用である、請求項1記載の培地組成物。
- 高密度培養用である、請求項1または2記載の培地組成物。
- 浮遊培養される細胞の細胞密度が6.0×105cells/mL以上である、請求項3記載の培地組成物。
- 細胞が、多能性幹細胞、成体幹細胞、または前駆細胞である、請求項1~4のいずれか一項記載の培地組成物。
- 請求項1記載の培地組成物において、細胞を浮遊培養することを含む、細胞の培養方法。
- bFGFが10~1000ng/mL/dayで、または、該濃度のbFGFと同等の効果を奏する濃度の安定化されたbFGFが培地に添加される、請求項6記載の方法。
- 浮遊培養される多能性幹細胞の細胞密度が6.0×105cells/mL以上である、請求項6または7記載の方法。
- 細胞が多能性幹細胞、成体幹細胞、または前駆細胞である、請求項6~8のいずれか一項記載の方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227028046A KR20220128647A (ko) | 2020-01-14 | 2021-01-13 | 세포 배양용 배지 조성물 |
JP2021571193A JPWO2021145319A1 (ja) | 2020-01-14 | 2021-01-13 | |
EP21740659.4A EP4092046A4 (en) | 2020-01-14 | 2021-01-13 | COMPOSITION OF CELL CULTURE MEDIUM |
CA3167723A CA3167723A1 (en) | 2020-01-14 | 2021-01-13 | Cell culture medium composition |
CN202180009999.4A CN115003791A (zh) | 2020-01-14 | 2021-01-13 | 细胞培养用培养基组合物 |
US17/863,546 US20230002729A1 (en) | 2020-01-14 | 2022-07-13 | Cell culture medium composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-003958 | 2020-01-14 | ||
JP2020003958 | 2020-01-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/863,546 Continuation US20230002729A1 (en) | 2020-01-14 | 2022-07-13 | Cell culture medium composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021145319A1 true WO2021145319A1 (ja) | 2021-07-22 |
Family
ID=76863888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/000744 WO2021145319A1 (ja) | 2020-01-14 | 2021-01-13 | 細胞培養用培地組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230002729A1 (ja) |
EP (1) | EP4092046A4 (ja) |
JP (1) | JPWO2021145319A1 (ja) |
KR (1) | KR20220128647A (ja) |
CN (1) | CN115003791A (ja) |
CA (1) | CA3167723A1 (ja) |
WO (1) | WO2021145319A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110494559A (zh) * | 2017-03-28 | 2019-11-22 | 味之素株式会社 | 不分化地维持用培养基添加剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012527880A (ja) * | 2009-05-29 | 2012-11-12 | ノヴォ ノルディスク アー/エス | hPS細胞由来の胚体内胚葉からの特定の内胚葉の派生 |
JP2013510567A (ja) * | 2009-11-12 | 2013-03-28 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
WO2013147264A1 (ja) | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 硫酸化化合物を含む幹細胞増殖用培地 |
JP2018184352A (ja) | 2017-04-24 | 2018-11-22 | アサマ化成株式会社 | 抗体を有効成分とするtnf産生抑制作用組成物 |
WO2019103129A1 (ja) * | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
JP2020003958A (ja) | 2018-06-26 | 2020-01-09 | ファナック株式会社 | 数値制御装置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015249110B2 (en) * | 2005-06-22 | 2017-12-21 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
CA2810488A1 (en) * | 2010-09-07 | 2012-03-15 | Technion Research & Development Foundation Limited | Novel methods and culture media for culturing pluripotent stem cells |
WO2018139548A1 (ja) * | 2017-01-26 | 2018-08-02 | 国立大学法人大阪大学 | 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法 |
CN111886334A (zh) * | 2018-03-20 | 2020-11-03 | 富士胶片株式会社 | 三维培养多能干细胞的方法 |
-
2021
- 2021-01-13 EP EP21740659.4A patent/EP4092046A4/en active Pending
- 2021-01-13 KR KR1020227028046A patent/KR20220128647A/ko active Search and Examination
- 2021-01-13 CN CN202180009999.4A patent/CN115003791A/zh active Pending
- 2021-01-13 CA CA3167723A patent/CA3167723A1/en active Pending
- 2021-01-13 JP JP2021571193A patent/JPWO2021145319A1/ja active Pending
- 2021-01-13 WO PCT/JP2021/000744 patent/WO2021145319A1/ja unknown
-
2022
- 2022-07-13 US US17/863,546 patent/US20230002729A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012527880A (ja) * | 2009-05-29 | 2012-11-12 | ノヴォ ノルディスク アー/エス | hPS細胞由来の胚体内胚葉からの特定の内胚葉の派生 |
JP2013510567A (ja) * | 2009-11-12 | 2013-03-28 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
WO2013147264A1 (ja) | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 硫酸化化合物を含む幹細胞増殖用培地 |
JP2018184352A (ja) | 2017-04-24 | 2018-11-22 | アサマ化成株式会社 | 抗体を有効成分とするtnf産生抑制作用組成物 |
WO2019103129A1 (ja) * | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
JP2020003958A (ja) | 2018-06-26 | 2020-01-09 | ファナック株式会社 | 数値制御装置 |
Non-Patent Citations (4)
Title |
---|
HUI-HSUAN KUO ET AL., NEGLIGIBLE-COST AND WEEKEND-FREE CHEMICALLY DEFINED HUMAN IPSC CULTURE |
LEVENSTEIN MARK E; LUDWIG TENNEILLE E; XU REN-HE; LLANAS RACHEL A; VANDENHEUVEL-KRAMER KAITLYN; MANNING DAISY; THOMSON JAMES A: "Basic fibroblast growth factor support of human embryonic stem cell self-renewal., Stem Cells", MATERIALS AND METHODS, CELL LINES AND CELL CULTURE, vol. 24, no. 3, 1 March 2006 (2006-03-01), pages 568 - 574, XP009133580, DOI: 10.1634/stemcells.2005-0247 * |
MORADI M, RIASI A, OSTADHOSSEINI S, HAJIAN M, HOSSEINI SM, NASR ESFAHANI MH: "P-127: The Effect of Supplementation of In Vitro Culture Medium with FGF2 on Ovine Embryo Development", INT J FERTIL STERIL., vol. 8, no. Suppl. 1, 30 November 2013 (2013-11-30) - 5 September 2014 (2014-09-05), pages 82 - 82, XP009538243, ISSN: 2008-0778 * |
See also references of EP4092046A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110494559A (zh) * | 2017-03-28 | 2019-11-22 | 味之素株式会社 | 不分化地维持用培养基添加剂 |
CN110494559B (zh) * | 2017-03-28 | 2023-10-31 | 味之素株式会社 | 不分化地维持用培养基添加剂 |
Also Published As
Publication number | Publication date |
---|---|
KR20220128647A (ko) | 2022-09-21 |
US20230002729A1 (en) | 2023-01-05 |
EP4092046A1 (en) | 2022-11-23 |
JPWO2021145319A1 (ja) | 2021-07-22 |
CA3167723A1 (en) | 2021-07-22 |
EP4092046A4 (en) | 2024-03-13 |
CN115003791A (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Paschos et al. | Advances in tissue engineering through stem cell‐based co‐culture | |
CN111117946B (zh) | 一种鼻粘膜类器官培养基及培养方法 | |
Azarin et al. | Development of scalable culture systems for human embryonic stem cells | |
JP5700301B2 (ja) | 多能性幹細胞からの神経堤細胞群の分化誘導方法 | |
Sun et al. | Functional cells cultured on microcarriers for use in regenerative medicine research | |
Cetinkaya et al. | Derivation, characterization and expansion of fetal chondrocytes on different microcarriers | |
KR20160033703A (ko) | 체세포로부터 신경 능선 세포로의 소분자 기반 전환 | |
WO2021145319A1 (ja) | 細胞培養用培地組成物 | |
CN110945115A (zh) | 神经组织的保存方法 | |
WO2018082690A1 (zh) | 一种诱导分化的细胞制备间充质干细胞的方法及调控靶点的组合 | |
US20230295570A1 (en) | Closed manufacturing processes for large scale manufacturing of pluripotent stem cell derived cells | |
CN109563485A (zh) | 通过诱导诱导多能干细胞的分化来培养角膜上皮细胞的方法及系统 | |
JP6981403B2 (ja) | 神経分化能を亢進させる神経幹細胞用培地 | |
Komura et al. | Optimization of surface‐immobilized extracellular matrices for the proliferation of neural progenitor cells derived from induced pluripotent stem cells | |
CN110951686A (zh) | 一种造血干细胞体外扩增培养体系和方法 | |
CN107164325B (zh) | MSCs来源的少突胶质细胞的制备方法及试剂盒 | |
US20150329826A1 (en) | Materials and methods for cell culture | |
WO2017082296A1 (ja) | 軟骨組織塊及びその製造方法、並びに幹細胞から軟骨組織塊を誘導するための培地 | |
WO2021145321A1 (ja) | 細胞の高密度培養方法 | |
WO2021145322A1 (ja) | 浸透圧低減培地 | |
WO2021193748A1 (ja) | Hepes含有培地 | |
WO2017082295A1 (ja) | 軟骨組織塊及びその製造方法、並びに幹細胞から軟骨組織塊を誘導するための培地 | |
EP4092101A1 (en) | Cell culture method | |
CN113832097B (zh) | 组合物及含有其的无血清、无饲养层干细胞培养基及应用 | |
Raju et al. | Stem cell culture processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21740659 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021571193 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3167723 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021740659 Country of ref document: EP Effective date: 20220816 |